📊 AVHHL Key Takeaways
Is AVITA Medical, Inc. (AVHHL) a Good Investment?
AVITA Medical exhibits severe financial distress with negative stockholders' equity of -$16.6M, negative operating cash flow of -$31.2M, and liabilities exceeding assets by $16.6M. Despite strong gross margins of 82.1%, the company burns cash rapidly with operating losses of -$42.5M on just $71.6M in revenue, indicating fundamental business model challenges that extend beyond product-level economics.
AVITA Medical’s fundamentals are very weak: revenue growth is minimal, margins are deeply negative, and losses remain severe relative to its revenue base. Financial health is the main concern, with negative equity, sub-1.0 liquidity ratios, and heavy cash burn creating meaningful balance sheet and funding risk despite strong gross margins.
AVITA Medical, Inc. Key Strengths (AVHHL)
- Exceptional gross margin of 82.1% demonstrates strong product pricing power and production efficiency
- Modest revenue growth of 1.0% YoY shows market traction despite operational challenges
- Zero long-term debt provides flexibility and eliminates refinancing risk in near term
- High gross margin of 82.1% indicates attractive unit economics before operating expenses
- Revenue is still growing modestly year over year, showing the business has not stalled completely
- No long-term debt reduces traditional leverage risk
AVHHL Stock Risks: AVITA Medical, Inc. Investment Risks
- Negative stockholders' equity of -$16.6M indicates technical insolvency and heightened bankruptcy risk
- Severe cash burn of -$31.2M in operating cash flow with only $10.2M cash on hand provides minimal runway
- Operating margin of -59.4% and net margin of -67.8% reveal massive operating losses that far exceed revenue generation capacity
- Current ratio of 0.57x indicates immediate liquidity crisis with liabilities exceeding current assets
- Free cash flow of -$32.2M demonstrates the company is not self-sustaining and dependent on external financing
- Negative stockholders’ equity and current ratio of 0.57x indicate significant financial stress
- Operating and free cash flow are deeply negative, implying continued dependence on external financing or balance sheet support
- Operating margin of -59.4% and net margin of -67.8% show the company is far from sustainable profitability
Key Metrics to Watch
- Cash runway and timeline to funding crisis given current burn rate
- Path to operating profitability and achievement of positive operating cash flow
- Revenue growth acceleration and ability to scale without proportional cost increases
- Stockholders' equity recovery and return to positive net worth
- Quarterly revenue growth acceleration versus operating expense growth
- Cash burn and ending cash balance relative to current liabilities
AVITA Medical, Inc. (AVHHL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
AVHHL Profit Margin, ROE & Profitability Analysis
AVHHL vs Healthcare Sector: How AVITA Medical, Inc. Compares
How AVITA Medical, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is AVITA Medical, Inc. Stock Overvalued? AVHHL Valuation Analysis 2026
Based on fundamental analysis, AVITA Medical, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
AVITA Medical, Inc. Balance Sheet: AVHHL Debt, Cash & Liquidity
AVHHL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: AVITA Medical, Inc.'s revenue has grown significantly by 11% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.39 indicates the company is currently unprofitable.
AVHHL Revenue Growth, EPS Growth & YoY Performance
AVHHL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $18.3M | -$10.6M | $-0.35 |
| Q3 2025 | $16.9M | -$13.2M | $-0.46 |
| Q2 2025 | $15.2M | -$9.9M | $-0.38 |
| Q1 2025 | $11.1M | -$13.9M | $-0.53 |
| Q3 2024 | $13.6M | -$8.7M | $-0.34 |
| Q2 2024 | $11.8M | -$10.4M | $-0.41 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AVITA Medical, Inc. Dividends, Buybacks & Capital Allocation
AVHHL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for AVITA Medical, Inc. (CIK: 0001762303)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AVHHL
What is the AI rating for AVHHL?
AVITA Medical, Inc. (AVHHL) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 93% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AVHHL's key strengths?
Claude: Exceptional gross margin of 82.1% demonstrates strong product pricing power and production efficiency. Modest revenue growth of 1.0% YoY shows market traction despite operational challenges. ChatGPT: High gross margin of 82.1% indicates attractive unit economics before operating expenses. Revenue is still growing modestly year over year, showing the business has not stalled completely.
What are the risks of investing in AVHHL?
Claude: Negative stockholders' equity of -$16.6M indicates technical insolvency and heightened bankruptcy risk. Severe cash burn of -$31.2M in operating cash flow with only $10.2M cash on hand provides minimal runway. ChatGPT: Negative stockholders’ equity and current ratio of 0.57x indicate significant financial stress. Operating and free cash flow are deeply negative, implying continued dependence on external financing or balance sheet support.
What is AVHHL's revenue and growth?
AVITA Medical, Inc. reported revenue of $71.6M.
Does AVHHL pay dividends?
AVITA Medical, Inc. does not currently pay dividends.
Where can I find AVHHL SEC filings?
Official SEC filings for AVITA Medical, Inc. (CIK: 0001762303) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AVHHL's EPS?
AVITA Medical, Inc. has a diluted EPS of $-1.74.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AVHHL's fundamental grade?
Based on our AI fundamental analysis in June 2026, AVITA Medical, Inc. has a D grade with 93% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AVHHL stock overvalued or undervalued?
Valuation metrics for AVHHL: ROE of N/A (sector avg: 15%), net margin of -67.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AVHHL's AI grade for 2026?
Our dual AI analysis gives AVITA Medical, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AVHHL's free cash flow?
AVITA Medical, Inc.'s operating cash flow is $-31.2M, with capital expenditures of $1.0M. FCF margin is -45.0%.
How does AVHHL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -67.8% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.57 (avg: 2).